Overview
- Trial results reported from the phase II CELIA study showed patients given the lowest tested dose of diranersen had about 54% less decline on a standard cognitive test compared with placebo over nearly two years.
- CELIA enrolled 416 people with early Alzheimer’s and tested three doses; the strongest effect came from a 60 mg dose delivered into spinal fluid by lumbar puncture every six months.
- Researchers reported that diranersen lowered markers of tau, the protein that forms damaging tangles inside neurons, because the drug uses RNA‑targeting gene‑silencing to cut tau production at its source.
- The treatment was largely tolerated but higher doses were linked to headaches, injection‑site pain and episodes of confusion, and investigators emphasized larger trials are needed to assess safety and long‑term benefit.
- If phase III trials confirm these findings, the drug would offer a different biological approach to current amyloid‑targeting treatments and could raise questions about testing capacity, patient access and how health systems adopt new dementia drugs.